Recent research, product and partnership news, and other newsworthy announcements from Terumo Blood and Cell Technologies
May 13, 2026
May 13, 2026
Terumo Blood and Cell Technologies and Steminent collaborate to advance MSC late-stage clinical manufacturing
Terumo Blood and Cell Technologies and Steminent Collaborate to Advance MSC Late-Stage Clinical Manufacturing
Collaboration focuses on automated, scalable MSC expansion to support clinical and commercial readiness
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions, and Steminent Biotherapeutics have entered into a strategic collaboration to accelerate late-stage manufacturing readiness for mesenchymal stem cell (MSC) therapies, addressing one of the key barriers to clinical scale-up and commercialization in regenerative medicine.
Mar 17, 2026
Taiwan Bio partners with Terumo Blood and Cell Technologies to advance automated Treg manufacturing on Quantum Flex
Taiwan Bio partners with Terumo Blood and Cell Technologies to advance automated Treg manufacturing on Quantum Flex
Taiwan Bio will leverage the Quantum Flex™ Cell Expansion System 3-in-1 workflow beyond CAR-T to support development of regulatory T-cell therapies
Terumo BCT, a medical technology company and global leader in blood management solutions, has entered into a collaboration with Taiwan Bio Therapeutics Inc. (Taiwan Bio) to transition regulatory T-cell (Treg) manufacturing onto the automated Quantum Flex platform, supporting a move from manual processes toward more scalable, repeatable production.
Mar 05, 2026
Mar 05, 2026
Terumo and CiRA Foundation Joint Research Selected for AMED Funding
Terumo and CiRA Foundation Joint Research Selected for AMED Funding
Establishing a Stable and Efficient Expansion Workflow for Scalable iPS Cell Manufacturing
Terumo Corporation (TSE: 4543) and the CiRA Foundation, a public interest organization for the transfer of induced pluripotent stem (iPS) cell technology to industry, have been selected for funding by Japan Agency for Medical Research and Development (AMED), the national medical R&D funding agency.
Mar 05, 2026
Mar 05, 2026
Terumo Blood and Cell Technologies introduces APAC C> Ecosystem Blueprint
Terumo Blood and Cell Technologies introduces APAC C> Ecosystem Blueprint
A collaborative integration model to enable practical, scalable cell and gene therapy delivery.
A collaborative integration model to enable practical, scalable cell and gene therapy delivery.
Feb 12, 2026
SunCoast Blood Centers strengthens blood supply in Southwest Florida with FDA-cleared automation from Terumo Blood and Cell Technologies
Founded on Valentine’s Day in 1949, SunCoast Blood Centers is the first blood center in Florida and the ninth in the U.S. to adopt the Reveos™ Automated Blood Processing System
Dec 10, 2025
Dec 10, 2025
Appleton’s Community Blood Center helps strengthen platelet supply with FDA-approved automation from Terumo Blood and Cell Technologies
Fifth U.S. site to deploy the Reveos™ Automated Blood Processing System, improving access to lifesaving blood products for hospitals and patients in need
Dec 03, 2025
Dec 03, 2025
Terumo Blood and Cell Technologies inaugurates Africa headquarters and regional training center to strengthen blood safety and health system capacity
Terumo Blood and Cell Technologies (Terumo BCT), officially inaugurated its new Africa headquarters and regional training center in Nairobi.
.jpg)
Nov 18, 2025
Nov 18, 2025
University of Chicago School of Medicine achieves first-ever automated 3-in-1 TCR-T manufacturing on Terumo Blood and Cell Technologies Quantum Flex Bioreactor
Terumo Blood and Cell Technologies (Terumo BCT), a global leader in cell and gene therapy technologies, today announced an advancement in T cell therapy manufacturing in a collaboration with Richard Koya, M.D., Ph.D., and his team at University of Chicago
Nov 12, 2025
Terumo Blood and Cell Technologies and Santersus AG collaborate on therapeutic apheresis technology for sepsis treatment
Sepsis is one of the most frequent causes of death worldwide, claiming nearly 11 million lives, accounting for 20% of all global deaths and taking more lives than cancer.
Sep 30, 2025
Kenya, Uganda and Côte d’Ivoire Partner with Terumo Blood and Cell Technologies to Build Coordinated National Care Frameworks for Sickle Cell Care
In a landmark move, the Ministries of Health of Kenya and Côte d’Ivoire, together with Uganda’s Joint Clinical Research Centre (JCRC) under the stewardship of the Uganda Ministry of Health, have signed three Memoranda of Understanding (MoUs) with Terumo
Sep 18, 2025
CSL Plasma and Terumo Blood and Cell Technologies Announce Completion of Nationwide Rollout of Rika Plasma Donation System
CSL Plasma and Terumo Blood and Cell Technologies (Terumo BCT) today announced that the Rika™ Plasma Donation System has been deployed in all CSL Plasma centers across the U.S.
Sep 02, 2025
Terumo BCT and PwC Belgium Partner to Break Barriers in Access to Advanced Cell and Gene Therapies
Terumo BCT, a medical technology company, and PwC Belgium today announce a new partnership focused on driving equitable and sustainable access to Advanced Therapy Medicinal Products (ATMPs).
Jun 18, 2025
Terumo Blood and Cell Technologies Demonstrates Integrated 3-in-1 CAR-T Workflow Using its Quantum Platform
Protocol published in Cytotherapy1 shows activation and viral transduction can be performed on Terumo BCT’s Quantum Cell Expansion System. Integration of the three critical steps in CAR-T manufacturing — activation, transduction and expansion — on a
.png)
May 12, 2025
Join Parachute implementing Terumo Blood and Cell Technologies’ Rika Plasma Donation System to enhance donor experience and help expand access to lifesaving therapies
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, announces that Join Parachute will be adopting the Rika™ Plasma Donation System, a next-generation plasma collection system engineered to streamline plasma collection and prior
Mar 18, 2025
Terumo Blood and Cell Technologies Partners with South Korea’s KBIOHealth to Help Develop Nation’s Cell and Gene Therapy Workforce
KBIOHealth to leverage Terumo BCT’s expertise, as well as Quantum Flex and Finia system, for advanced training programs aimed at growing CGT manufacturing in Korea and beyond
Feb 25, 2025
National Alliance of Sickle Cell Centers and Terumo Blood and Cell Technologies Working Together to Improve Outcomes for Patients with Sickle Cell Disease
The BET on Blood for SCD collaboration aims to improve the lives of Sickle Cell Warriors by connecting healthcare providers with education about proven treatments to help manage the disease
Jan 29, 2025
Jan 29, 2025
Carter BloodCare First to Complete the Transition to Automated Whole Blood Processing With Terumo Blood and Cell Technologies
Lakewood, CO, U.S.A. – Terumo Blood and Cell Technologies (Terumo BCT), a global leader in blood management solutions, today announces that Carter BloodCare is the first U.S. adopter of its Reveos™ Automated Blood Processing System and Lumia™ Software
Jan 21, 2025
Terumo Blood and Cell Technologies and Akron Bio Complete Collaborative Study on MSC Expansion Using Quantum Flex
Study confirms that Terumo BCT’s Quantum Flex platform, paired with Akron Bio’s GMP virus-inactivated fibronectin reagent, provides a scalable and compliant solution for MSC expansion
.png)
.png)
Jan 20, 2025
Terumo Blood and Cell Technologies Reaches Strategic Partnership With Shandong Institute of Medical Devices and Pharmaceutical Packaging Inspection to Facilitate High-Quality Development of China’s Medical Device Industry
Hangzhou, China – Terumo Blood and Cell Technologies (Terumo BCT), a global medical technology company specializing in blood and cell processing, has signed a Memorandum of Understanding (MoU) on a strategic partnership with the Shandong Institute of Medi
Jan 17, 2025
Study Highlights Blood Supply Sustainability Through Ecosystem of Advanced Technologies and IT Systems at the Blood and Tissue Bank of Aragón
Blood centers globally face pressBlood centers ures from demographic changes, rising costs and evolving treatment demands. For BTBA, the aging donor population and difficulty retaining younger donors further strain the balance of blood supply and demand.
Jan 14, 2025
Jan 14, 2025
Terumo Blood and Cell Technologies and FUJIFILM Irvine Scientific Collaborate to Accelerate T Cell Expansion for Cell Therapy Developers
Turnkey solution helps simplify and scale T cell expansion using Fujifilm's PRIME-XV® T Cell Expansion Media on Terumo BCT’s Quantum Flex™ Cell Expansion System, easing the burden for developers
Dec 03, 2024
Dec 03, 2024
Multi-Center Superiority Clinical Trial, Supported by Terumo Blood and Cell Technologies, Aims to Significantly Reduce Complications From Acute Chest Syndrome in Adult Sickle Cell Disease Patients
Lakewood, Colorado, U.S.A. – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, announced funding support for a new clinical trial.
Dec 21, 2024
Nov 21, 2024
Patients, Scientists Agree: Automated Red Blood Cell Exchange Enhances Quality of Life in Sickle Cell Disease Patients
Recent peer-reviewed study sRecent peer-reviewed study supports what patients shared with their own voiceupports what patients shared with their own voices: Automated red blood cell exchange improves the lives of people struggling with sickle cell disease
Recent peer-reviewed study supports what patients shared with their own voices: Automated red blood cell exchange improves the lives of people struggling with sickle cell disease
Nov 14, 2024
Nov 14, 2024
Terumo Blood and Cell Technologies Unlocks New Chapter of Localization in China to Facilitate Blood and Cell Treatment Options for Patients
Hangzhou, China – Terumo Blood and Cell Technologies ("Terumo BCT") today held a localization launch ceremony themed "Unlocking a New Chapter in China, Led by Purpose, Built on Quality" in Hangzhou, Zhejiang Province.
Terumo BCT announced a strategic partnership with Terumo Medical Products (Hangzhou) Co., Ltd., investing in its production facility located in the Qiantang District, Hangzhou, seeking to provide high-quality locally made medical products for the Chinese market.
Oct 29, 2024
Oct 29, 2024
Terumo Blood and Cell Technologies advances the adoption of automated manufacturing to bring novel cell and gene therapies to more Latin American patients
The company is starting in Brazil, Colombia and Mexico, seeking to improve efficiency and cost-effectiveness in the manufacturing process for companies in the region
The company is starting in Brazil, Colombia and Mexico, seeking to improve efficiency and cost-effectiveness in the manufacturing process for companies in the region
Oct 02, 2024
Oct 03, 2024
Terumo Blood and Cell Technologies and Sanquin to automate whole blood processing across the Netherlands
Terumo Blood and Cell Technologies and Sanquin to automate whole blood processing across the Netherlands
Sanquin integrates Terumo BCT’s Reveos™ Automated Blood Processing System to enhance blood processing efficiency and increase production of essential blood products
Sanquin integrates Terumo BCT’s Reveos™ Automated Blood Processing System to enhance blood processing efficiency and increase production of essential blood products
Sep 22, 2024
Sep 23, 2024
Terumo Blood and Cell Technologies collaborates with Nova Biomedical to bring automated cell culture sensing to Quantum Flex
Integration of Nova’s BioProfile® FLEX2 will enable automated cell culture analyses for process development through commercial manufacturing with Quantum Flex
Integration of Nova’s BioProfile® FLEX2 will enable automated cell culture analyses for process development through commercial manufacturing with Quantum Flex
Sep 11, 2024
Sep 11, 2024
Anthony Nolan to open stem cell collection centre to help patients and enable cell and gene therapy research
Stem cell charity Anthony Nolan has announced the opening of the Anthony Nolan Cell Collection Centre in Nottingham, U.K.
Stem cell charity Anthony Nolan has announced the opening of the Anthony Nolan Cell Collection Centre in Nottingham, U.K.
Aug 14, 2024
Aug 15, 2024
Terumo Blood and Cell Technologies and Charles River demonstrate versatility of FINIA automated cell and gene therapy fill and finish platform
New publication confirms the ability of Terumo BCT’s FINIA™ Fill and Finish System to automate large volumes across multiple autologous and allogeneic cell and gene therapy workflows.
New publication confirms ability of Finia Fill and Finish System to automate large volumes across multiple autologous and allogeneic cell and gene therapy workflows
Jul 09, 2024
Jul 10, 2024
Terumo Blood and Cell Technologies celebrates 60 years as a community-first Colorado company
Pioneering the manufacturing of the next wave of blood and cell-based treatments using its automation technologies.
Pioneering the manufacturing of the next wave of blood and cell-based treatments using its automation technologies
Jun 18, 2024
Jun 19, 2024
Mariah J. Scott: Write Your Own Story, a sickle cell warrior fights for motherhood
Mariah J. Scott was told by doctors that she shouldn't have children because of her sickle cell disease. She thought her dreams of motherhood were doomed. But that didn't stop Mariah from writing her own story.
A self-described Sickle Cell Warrior, epidemiologist, and patient advocate, Mariah J. Scott shares her powerful story through self-advocacy, pain crises and pregnancy.
May 20, 2024
May 21, 2024
Terumo Blood and Cell Technologies adds Mani Venkatesh to executive team as VP of Digital Transformation
In the new role, Venkatesh will maximize the use of previous digital investments and oversee research and development, cybersecurity, and data privacy related to adopting emerging technologies.
Feb 19, 2024
Feb 19, 2024
Terumo Blood and Cell Technologies-sponsored panel publishes first-of-its-kind international consensus recommendations for pregnancy complications in patients with sickle cell disease
Multidisciplinary experts from the U.S., Europe and Turkey used iterative Delphi methodology to develop guidance for therapeutic interventions based on the unique needs of pregnant patients with sickle cell disease.
Experts develop guidance for therapeutic interventions based on unique needs of pregnant patients with sickle cell disease
Feb 14, 2024
Feb 14, 2024
Hundreds of sickle cell patients to benefit from £1.5M technology investment
Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following the announcement of a £1.5M investment in 25 red blood cell exchange devices.
UK's National Health Service to use Spectra Optia to help manage sickle cell disease
Dec 04, 2023
Dec 05, 2023
Terumo Blood and Cell Technologies takes part in Connecting the Dots: a new film series showcasing the pivotal role of medical technologies to improve healthcare
See how an Austrian police officer fighting leukemia is helped by a stem cell donation from his sister — just one way that apheresis technology helps make potentially curative cell therapies more accessible.
A police officer fighting leukemia, a stem cell donation from his sister —and how apheresis technology helps make potentially curative cell therapies more accessible
Nov 14, 2023
Nov 15, 2023
Action Center teams with Terumo BCT to provide Thanksgiving meals for over 5,700 Jefferson County residents
Terumo BCT steps in to ensure local Thanksgiving tradition continues in 2023.
Terumo Blood and Cell Technologies steps in to ensure local Thanksgiving tradition continues in 2023
Nov 05, 2023
Nov 06, 2023
908 Devices and Terumo Blood and Cell Technologies collaborate to add on-line analytics to Quantum Flex Cell Expansion System
Automation combined with on-line monitoring during the cell expansion step can bring cell therapy manufacturing efficiencies and enable increased patient accessibility and safety
Automation combined with on-line monitoring during cell expansion can bring cell therapy manufacturing efficiencies and enable increased patient accessibility and safety
Oct 30, 2023
Oct 31, 2023
Proven therapy can help thousands more patients with rare diseases – if they can access it
One such instance is what's known as therapeutic apheresis. Apheresis is the process of simultaneously separating blood components, isolating certain parts, and returning the rest to the donor or patient.
Not every disease will need an expensive, cutting-edge treatment, and sometimes the tools to improve patient health are here today, hiding in plain sight, like therapeutic apheresis
Oct 04, 2023
Oct 05, 2023
Terumo Blood and Cell Technologies launches study with BioCentriq® to generate public CAR-T cell data using Terumo BCT’s CGT manufacturing platforms
Data will detail how the Terumo BCT’s Quantum Flex® Cell Expansion System and Finia® Fill and Finish System with BioCentriq’s LEAP™ Advanced Therapy Platform can help accelerate delivery of CAR-T therapies to patients.
Data will detail how the Terumo BCT’s Quantum Flex Cell Expansion System and Finia Fill and Finish System with BioCentriq’s LEAP™ Advanced Therapy Platform can help accelerate delivery of CAR-T therapies to patients
Sep 20, 2023
Sep 21, 2023
Terumo Blood and Cell Technologies collaborates with MCQ to enable automated gas mixing for expansion of cell and gene therapies
Pairing of MCQ Nano 3 enables custom gas mixing for the Quantum Flex® Cell Expansion System
Pairing of MCQ Nano 3 enables custom gas mixing for the Quantum Flex Cell Expansion System
Sep 18, 2023
Sep 19, 2023
Terumo Blood and Cell Technologies appoints Jackie Kunzler to head Research and Development
Kunzler possesses over 20 years of experience leading highly successful teams and product launches
Kunzler possesses over 20 years of experience leading highly successful teams and product launches
Sep 06, 2023
Sep 06, 2023
Terumo Blood and Cell Technologies' peer-reviewed publication shows hollow fiber-based bioreactors can produce 8x viral vector-producing cells in four days
Quantum technology optimized for automated expansion of cell and gene therapy components
Quantum technology optimized for automated expansion of cell and gene therapy components
Aug 01, 2023
Aug 01, 2023
Terumo Blood and Cell Technologies’ Reveos® Automated Whole Blood Processing System cleared by FDA for U.S. commercial use
In many disasters and critical need scenarios – like mass shootings, natural disasters, or large-scale accidents, a significant amount of blood is required immediately.
Reveos is positioned to help U.S. blood centers supplement the platelet supply, reduce labor and costs, and improve overall operational efficiency
May 30, 2023
May 30, 2023
Government of Meghalaya and Terumo Blood and Cell Technologies launch behavioural change campaign for voluntary blood donation in Ri-Bhoi District
The campaign's primary objective is to foster a cultural shift in Ri-Bhoi District, encouraging individuals to embrace voluntary blood donation as a noble act that can save lives.
The Health Minister of Meghalaya, Dr. Mazel Ampareen Lyngdoh launched the campaign at Parish Hall, Nongpoh
May 25, 2023
May 25, 2023
Terumo Blood and Cell Technologies optimizing cell therapy production through industry’s first apheresis training for cell therapy manufacturers
Terumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia® Apheresis System at major conferences.
Terumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia® Apheresis System at major conferences
May 16, 2023
May 16, 2023
Terumo Blood and Cell Technologies appoints Veerle d’Haenens as General Manager, Cell Therapy Technologies
d’Haenens to leverage portfolio synergies between Therapeutic Systems and Cell Therapy Technologies businesses to drive growth and shape cell therapy ecosystem
d’Haenens to leverage portfolio synergies between Therapeutic Systems and Cell Therapy Technologies businesses to drive growth and shape cell therapy ecosystem
Feb 23, 2023
Feb 23, 2023
Terumo Blood and Cell Technologies presents First Quantum Flex data for multiple size bioreactors showing rapid T-cell expansion to numbers equivalent to a therapeutic dose
Presentation at CAR-TCR Summit Europe demonstrates scalability and reduced media usage enable lower cost to produce a dose of autologous T-cell therapy.
Presentation at CAR-TCR Summit Europe demonstrates scalability and reduced media usage enable lower cost to produce a dose of autologous T-cell therapy
